关于菲律宾皇家航空马尼拉中国航线核酸检测的最新通知

更新日期: 2021年05月06日

更新内容: 检测费收款账户之一有更改!

● 核酸检测+第一次抗体检测(旅客自费,共计1750人民币/人):

【检测机构】St. Luke's Medical Center Global City [MAIN ENTRANCE -正门] 【地址】Rizal Drive corner 32nd Street. and 5th Avenue Taguig

(https://goo.gl/maps/MxUunPF6bQxuYFzf8)

● 第二次抗体检测(航司免费提供)

【检测机构】Safeway diagnostic laboratory center

【地址】Ground Floor, Centillion Center Bldg., 2972 Ramon Magsaysay Blvd. Sta.

Mesa, Manila, Philippines

【马尼拉联系人】Lovely 【联系电话】:09175477843

重要提示★检测时间

◇ 不是在航司指定团队监督下的检测视为无效;未能按通知预约时间到达检测的视为放弃!

航班	核酸+抗体	检测	第二次抗体	航班日期	
BUCAL	检测日期	检测时间	检测日期	检测时间	別加江口光
	5月10 (周1)	0700-1100	5月11 (周2)	0800-1100	2021/5/12
	5月17 (周1)	0700-1100	5月18 (周2)	0800-1100	2021/5/19
	5月24 (周1)	0700-1100	5月25 (周2)	0800-1100	2021/5/26
	5月31 (周1)	0700-1100	6月01 (周2)	0800-1100	2021/6/2
	6月07 (周1)	0700-1100 6月08 (周2)		0800-1100	2021/6/9
	6月14 (周1)	0700-1100	6月15 (周2)	0800-1100	2021/6/16
	6月21 (周1)	1) 0700-1100 6月22		0800-1100	2021/6/23
	6月28 (周1)	0700-1100	6月29 (周2)	0800-1100	2021/6/30
	7月05 (周1)	0700-1100	7月06 (周2)	0800-1100	2021/7/7
	7月12 (周1)	0700-1100	7月13 (周2)	0800-1100	2021/7/14
	7月19 (周1)	0700-1100	7月20 (周2)	0800-1100	2021/7/21
RW368	7月26 (周1)	0700-1100	7月27 (周2)	0800-1100	2021/7/28
马尼拉-无锡	8月02 (周1)	0700-1100	8月03 (周2)	0800-1100	2021/8/4
09:30-13:00	8月09 (周1)	0700-1100	8月10 (周2)	0800-1100	2021/8/11
	8月16 (周1)	0700-1100	8月17 (周2)	0800-1100	2021/8/18
	8月23 (周1)	0700-1100	8月24 (周2)	0800-1100	2021/8/25
	8月30 (周1)	0700-1100	8月31 (周2)	0800-1100	2021/9/1
	9月06 (周1)	0700-1100	9月07 (周2)	0800-1100	2021/9/8
	9月13 (周1)	0700-1100	9月14 (周2)	0800-1100	2021/9/15
	9月20 (周1)	0700-1100	9月21 (周2)	0800-1100	2021/9/22
	9月27 (周1)	0700-1100	9月28 (周2)	0800-1100	2021/9/29
	10月04 (周1)	0700-1100	10月05 (周2)	0800-1100	2021/10/6
	10月11 (周1)	0700-1100	10月12 (周2)	0800-1100	2021/10/13
	10月18 (周1)	0700-1100	10月19 (周2)	0800-1100	2021/10/20
	10月25 (周1)	0700-1100	10月26 (周2)	0800-1100	2021/10/27

温馨提示:

- 1、 做检测按照上表日期/时间,不用预约。三次检测的结果为阴性(**核酸阴性;两次抗体检测要求IGM和IGG都为阴性**)的旅客,可正常值机;检测结果为阳性的旅客,将被拒绝乘机。
- 2、 检测当天请带笔、护照原件和三份护照复印件(两份用于第一次检测,一份用于第二次 检测);如果旅客的护照正在移民局办理申请,必须携带移民局相关证明(必须有移民局签 字和L0G0);如果旅客没有护照,必须有证明护照是已报失。**不符合以上条件的旅客将不** 被允许参加检测,旅客所购机票视为放弃。
- 3、 核酸检测当天请在工作人员指导下加入微信群,以便旅客收取检测报告扫描件后申请HS 码。乘机的旅客请在航班起飞当日在机场柜台处领取检测报告原件。如有问题,请务必于检测当日与现场工作人员沟通。
- 4、 进行核酸检测和第一次抗体检测时,检测医院的儿科医生上班时间为早上10:30。出于安全考虑,请有陪同婴儿和9岁(含)以下儿童的客人尽量在检测当天早上10:30到达医院进行检测。
- 5、 在医院填表(请正确填写名字和护照号码,避免检测报告出来后有误)。
- 6、 核酸检测和第一次抗体检测共计**1750人民币/人**(第一次抗体检测增加IGG检测,检测费用上调至1750人民币/人),第二次抗体检测由航司免费提供。
- 7、 检测费请务必提前一天支付,检测费1750人民币/人请汇入以下账户: 【注意:汇款时必须备注乘机人姓名和航班号 ,方便核对;如果没有备注名字或汇错账户,旅客须现场重新付款参加检测;检测当天请把汇款截图给现场航司工作人员查看,以做证明,感谢配合。】

血清和核酸检测流程

正门入口处, 在保安那边拿第一张表(健康申明), 填完给保安查看。

* 如果大堂里有很多人,请在外面排队,

大堂里的人少一些保安会让你进去的时候.*



正门进去后, 右手边再拿第2张表格,填写清楚后交给负责人。

* 检查付款证明 (截图必须有旅客名字)*



请稍安勿燥,等候叫名字面试。 面试后, 请等候叫名字进行检测:

- 1. 先做血清
- 2. 做完血清,必须去排队拍照
- 3. 拍完,与大使馆报名*写清楚中文名字*
 - 4. 报名完, 做核酸检测



做完核酸检测,可以回家了! (你们要飞当天会有人把报告原件送去机场给你们)


LVH 01.13.2021

中文名必须【正楷字体】, 一笔一划写自己的名字,

【不要潦草字体】

序号 # No.	姓 (拼音) Surname	名 (拼音) First Name	中文名 Chinese Name	性别 Gender	出生日期 Birthdate	护照号 Passport No.
1			正楷字体,			
2			不要潦草字体			

名字看不清楚, 无法审批 HS 绿码



In Re:

P
-Applicantx

ORDER

On 04 November 2020, applicant filed a request for updating of stay and permission to leave. Records disclose:

"" OT No TUN 30 44 022

Arrival date: 07 December 2019 No. of months requested: 11
Admission: 9a-30 days (VUA) Months overstayed: 10
Latest authorized stay: 06 January 2020 Application filed by: Applicant

 Applicant bears no derogatory record as of 04 November 2020 based on the attached Certification issued by Catalino Z. Alfonso;

b. Applicant has Thirty Day (30) Temporary Visitor's Visa Upon Arrival (TV-VUA) with operator:

c. Applicant provides confirmed ticket to Wuxi via RW368 dated 18 November 2020; and

d. Applicant failed to leave the country based on itinerary indicated without valid justification, in violation of the terms and conditions pursuant to his/her VUA order.

We note that the Department of Justice Circular No. 001, Section 3(b), dated 08 January 2020, expressly provides that "No Extension or Renewal of a TV-VUA shall be allowed".

WHEREFORE, premises considered, Applicant is hereby ORDERED:

1. To pay updating fees, fines, and penalties;

- 2. To secure Emigration Clearance Certificate (ECC) and NBI Clearance;
- 3. To leave on 18 November 2020; and
- To be barred from entering the country pursuant to Department of Justice Circular No. 001.

The Tourist Visa Section shall implement this Order.

SO ORDERED.

Recommend (1) by() 4 2023

ATTY. RUBEN C. CASIBANG, JR. Head, SOCI

APPROVED / DISAPPROVED

JAIME H. MORENTE

Commissioner

PATRIOTISM . INTEGRITY . PROFESSIONALISM



REPUBLIC OF THE PHILIPPINES DEPARTMENT OF JUSTICE BUREAU OF IMMIGRATION MAGALLANES DRIVE, INTRAMUROS 1002 MANRIA

In re:

Travel Doc. N CHN Female

ORDER

On 30 October 2020, Tourist Visa Section (TVS) endorsed to the Im date application for Temporary Vistor is Regulation Divisior.

Records show: (i) On 22 January 2020, NAIA-based immigration authorities I valid stay ended on 29 January 2020; and (iii) ** arstayed for 10 months in the country. admitted .

To address the foregoing, we order *** **** to:

- 1. Pay immigration fees, fines and penalties to be computed from by Tourist Visa Section (TVS);
- 2. Pay IARC amounting Php15,000.00 and Express Lane Fee amounting to Php10,000.00;
- 3. Secure Emigration Clearance Certificate; and
- 4. LEAVE the Philippines via NAIA within thirty (30) days from receipt of this Order.

TVS and ARD shall insure the implementation of this Order.

Give copies of this Order to *** - 3.

IT IS SO ORDERED.

Prepared by:

Recommending Approval:

ROGELIO D. GEVERO JR

Date signed: 9 3 NOV 2020

Chief, Immigration Regulation Division

M RAUL A. MEDINA Acting Chief, Tourist Visa Section

Date signed: POT 3 11 7079

APPROVED/DISAPPROVED

JAIME H. MORENTE

Commissioner 02 20 Date signed:_


核酸检测+第一次抗体检测地址:



必须在医院大门口进去开始检测操作。 不允许自己去急诊室做核酸测, 必须按照我们给出的预约方式做,如有自己跑 去急诊室做的不予登机!

第二次抗体检测地址:





去医院检测必须戴口罩和面罩(两种都要戴)!

下图为面罩(参考):



下图为口罩:







去医院检测不可以戴以下类型的口罩














正门入口处, 在保安那边拿第一 张表 (健康申明), 填完给保安查看。

The data that you provide is strictly confidential and used for hospital referent 也無限的能力 (化聚苯甲酚 - 基础 - 基	ice only.
姓名: 年齡: 性別: 联系方式: am a () Patient () Visitor () Companion (VOthers: SWAB	
我是 患者 访客 同伴 其他	是 否
Please tick an answer for every question item 以下问题请国答是与否:	YES NO
Have you been recently tested for COVID-19? 近期是否做过核酸检测?	
Date swabbed: 如有,取样时间: Result (if available): 檢測結果(如有) Have you been evaluated as Probable or Suspected for COVID-19? 是否被诊断为联叙树	als . /
If YES, when did your quarantine start? 如是,隔离期开始日期是?	T- V
Do you have any travel history in the past 14 days? 近14天是否有旅行记录?	./
If YES, when and where? 如有,请提供外出日期和到访地点	
Did you come in close contact or staying in the same close environment with	
someone who is a confirmed COVID-19 case? 您是否与确诊患者有密切接触或住在同一密闭环境	a
Did you come in close contact with a Probable or Suspected person with COVID-19?	,
您是否与疑似病例有过密切接触?	
Have you experienced the following symptoms recently? 您證期是否在以下症状?	
Fever (>38°C) 发烧 (高于38度)	1./
Diarrhea, Nausea, or Vomiting 腹泻、恶心或呕吐	
Shortness of breath or other respiratory symptoms 呼吸急促或其他呼吸道症状	1 3
Other respiratory symptoms: 具体症状:	
Headache 头疼	□ □ √ .
Joint Pain or Muscle Pain 关节箱或肌肉箱	
Flu-like symptoms such as:类似流感的症状,例如:	,
Chills or repeated shaking with chills 畏寒或反复打寒战	V,
Body aches 浑身酸缩	√ ,
Sore throat 咽喉痛	√ ,
Runny Nose or Sneezing	V,
Cough and colds 咳嗽和感冒	V/
New loss of smell and/or taste 近期丧失嗅觉和味觉	V/
Eye discharge 眼睛出现分泌物 Skin rash or discoloration of toes/fingers 皮疹或手胸趾变色	- ·
	- ·/
Loss of speech or movement 丧失语言和行动功能	V

SLMC-IPC-5-56 REV01 (May 14, 2020)

正门进去后,右手边再拿第2张表格,填写清楚 后交给负责人。请稍安勿燥,等候叫名字面试。

Philippine Integ					Cas	e Invest	igation Form		J	題目有星 ^日	· , 必	须填,	没有的记		
Disease Survei and Response	lance				Corona	virus Di: Ver	us Disease (COVID-19) Version 8								
advised that DRUs	are only	allowed	to obtain 1 co	py of accor	nplished C	IF from a p	patient.						11-		
	IUL a CIIC	CK IIIdis	. on the appro												
eporting offic				DNO NE	giornanion	TOMINE									
Name of Interviewer						of Intervie	wer								
Name of Informant (if applicable)					ıship				Contact Nu	mber of Informant					
If existing case Not applicable (Unknown Update symptoms					Update case classification Update lab result					Update exp Others, spe	oosure / tr ecify:				
								n							
		ii that a	opiy, rejer to A	ppenaix 2)	1 4		8 11 11	0 1	E 11 F	□ 6	шп				
e* ₁₄				First Na	me (and S	uffix)*~	rito		Middle Nar	ne* N/	Δ				
						- 4	Ť	-		14/			Female #		
四期(7月)日)生)					in .			WA 1939	U M	~ 男	-	- C		
on 职业							☐ Yes		□ No		_	Unknow	m		
						rovide ad		f patient li	ves in closed	settings, see	1.5) 🖽	n菲律:	计划性		
House No./Lot/Bldg.* 门牌号/楼名 Street/Puro					0名					Municipal	ity/City*	城市			
Province* 省 Home Phon					rea Code)	家电话		手机号码	}	Email Add	ress (子邮箱			
. Permanent Add	fress an	d Conta	ct Informatio	n (if differ	ent from	current a	ddress) ≥2 mm m .	ân.92.99	上而不一样						
House No./Lot/Bldg. 门龍号/楼名 Street/Puro					is		Barangay	AMARIAN.		Municipal	ity/City	城市			
Province 🖺 Home Phon											Email Address 由子能範				
Current Works	lace Arli	dross ar	nd Contact Inf	ormation	TAL	eh tel-									
Lot/Bidg. 门牌号/楼名 Street						COAL	Barangay Municipality/City 城市								
Province 😩 Name of Wo				rknlace 7	作品的	2 W						Ď.			
												u 7			
		ficate fu	Name & locat	on exposus	re and tra	wel histor	y in Part 3)					_	No		
					etti sucinty		and OFW:	□ OF	w 🗆 N	on-OFW		·	No		
lational Traveler*		Yes,	Country of or	igin: CH	INA								No		
	/ 0	Yes,	City, Municip	ality, & Pro	ovince of o	origin						•	No		
ocal Traveler*	-	Var							on Outside Re	sidence / Loc	al Travele		No		
losed Settings*	15					ent comm						-	NO		
us Person*			specify group									•	No		
se Investigation C															
	formati	ion	ion?	Ver 5		t Control	/MM/DD/YYYYI*					_	No		
. Consultation In	lated co														
Consultation In vious COVID-19 rel facility where first	lated co	was do	ne		ate of Firs		(MANUELY TYTE)					•	110		
vious COVID-19 rel facility where first Disposition at T	lated co consult			ne of hosp			antine facility)					•	NO.		
vious COVID-19 rel facility where first Disposition at T mitted in hospital	consult	Report'	(Provide nan	ne of hosp			antine facility) Date and Time admit					-	NO.		
vious COVID-19 rel facility where first Disposition at T mitted in hospital mitted in isolation/	consult fime of	Report'	(Provide nan	ne of hosp			antine facility) Date and Time admit	ed/quaran	tined in facili	Y		-	NO.		
vious COVID-19 rel facility where first Disposition at T mitted in hospital mitted in isolation/ nome isolation/qua charged to home	consult consult fime of quaran grantine	Report' tine fac	(Provide nam	Discharge	ital/isolat	/mm/*_	antine facility) Date and Time admit Date and Time isolate Date and Time isolate	ed/quaran ed/quaran	tined in facili tined at hom Other	:					
vious COVID-19 rel facility where first Disposition at T mitted in hospital mitted in isolation/ nome isolation/que charged to home Health Status a	consult consult ime of quaran arantine t Consu	Report'	Provide name	Discharge	ital/isolat	/mm/*_	antine facility) Date and Time admit Date and Time isolate Date and Time isolate Mild	ed/quaran ed/quaran	tined in facili tined at hom Other derate	: Severe					
vious COVID-19 rel facility where first Disposition at T mitted in hospital mitted in isolation/que charged to home Health Status a Case Classificat	consult ime of quarant arantine t Consultion* (Re	Report'	Provide name	Discharge	ital/isolat	/mm/*_	antine facility) Date and Time admit Date and Time isolate Date and Time isolate	ed/quaran ed/quaran	tined in facili tined at hom Other derate	: Severe	DVID-19 (
vious COVID-19 rel facility where first Disposition at T mitted in hospital mitted in isolation/que charged to home Health Status a Case Classificat Clinical Informa	lated co consult fime of 'quarant arantine t Consultion* (Re ation	Report' tine fac tine	Provide name	Discharge	ital/isolat	/mm/*_	antine facility) Date and Time admit Date and Time isolate Date and Time isolate Mild Probable	ed/quaranted/quarant	tined in facili tined at hom Other derate ifirmed	Severe	DVID-19 C				
vious COVID-19 rel facility where first Disposition at T nitted in hospital_ nitted in isolation/ nome isolation/qua charged to home Health Status a Case Classificat Clinical informa inset of illness (MM	consult lime of 'quaranterantine t Consult t Consultion' (Resistion M/DD/Y	Report* tine fac If disch ilt* (Refi efer to A	(Provide namility	Discharge	ital/isolat	/mm/*_	antine facility) Date and Time admit Date and Time isolate Date and Time isolate Mild	ed/quaranted/quarant	tined in facili tined at hom Other derate ifirmed	Severe	DVID-19 C				
vious COVID-19 rel facility where first Disposition at T mitted in hospital mitted in isolation/que charged to home Health Status a Case Classificat Clinical Informa	dated co consult firme of i 'quarantine t Consultine' (Re ation M/DD/Y k all tho	Report' time fac If disch ilt* (Refi efer to A	(Provide namility arged: Date of er to Appendix 1)	Discharge	ital/isolat	/mm/*_	antine facility) Date and Time admit Date and Time isolate Date and Time isolate Mild Probable	ed/quaranted/quarant	tined in facili tined at hom Other derate ifirmed	Severe Non-CC	DVID-19 C	- Cr			
wous COVID-19 rei facility where first a Disposition at T mitted in hospital mitted in isolation/ some isolation/que charged to home Health Status a Clinical Informa inset of Illness (IMI ISymptoms (Checimptomatic er "C"	dated co consult fime of /quaran arantine t Consult ion* (Re stion M/DD/Y k all tha	Report' tine face If discheder to A YYYY)* Dyspne Anorexi	(Provide name ility	Discharge	ital/isolat	/mm/*_	antine facility) Date and Time admit Date and Time isolate Date and Time isolate Mild Probable Comorbidities (Chec	ed/quaranted/quarant	tined in facili tined at hom Other derate ifirmed	Severe Non-CC	rointestin to-urinary	Case			
vious COVID-19 rei facility where first Disposition at T mitted in hospital_ nitted in isolation/ iome isolation/ iome isolation/ iome isolation/ charged to home Health Status a Case Classificat Clinical Informa inset of illness (MM ISymptoms (Chec imptomatic er	dated co consult fime of 'quarant arantine t Consulton* (Re atton M/DD/Y k all tha	Report* tine face If discheder to A YYYY)* Dyspne Anorexi Nausea	(Provide namility	Discharge	ital/isolat	/mm/*_	antine facility) Date and Time admit Date and Time isolate Date an	ed/quaranted/quarant	tined in facili tined at hom Other derate ifirmed	Severe Non-CC	rointestin to-urinary rological D	Case			
wous COVID-19 rei facility where first a Disposition at T mitted in hospital mitted in isolation/ some isolation/que charged to home Health Status a Clinical Informa inset of Illness (IMI ISymptoms (Checimptomatic er "C"	dated consult ime of duarantine of duarantine of tensus ion* (Resistion M/DD/Y & all the dual dual dual dual dual dual dual dual	Report' tine face If discheder to A YYYY)* Dyspne Anorexi	(Provide namility arged: Date of er to Appendix 1)	Discharge	ital/isolat	/mm/*_	antine facility) Date and Time admit Date and Time isolate Date and Time isolate Date and Time isolate Mild Probable Comorbidities (Chee	ed/quaranted/quarant	tined in facili tined at hom Other derate ifirmed	Severe Non-CC	rointestin to-urinary rological D	Case			
wous COVID-19 rei facility where first Disposition at T initted in hospital mitted in insolution mitted in solution the health Status at Case Classificat Clinical Informa inset of illness (MI Symptoms (Checi mptomatic er "C giph meral weakness gue duche duc	dated consult ime of incomment incom	Report' tine fac If disch lit* (Ref lefer to A 'YYY)* _ It apply Dyspne Anorexi Nauseli Noisrhe Altered	(Provide namility	Discharge 3)	ital/isolat	/mm)*_ matic	antine facility) Date and Time admit Date and Time isolate Date and Time isolate Date and Time isolate Date and Time isolate Mild Probable Comorbidities (Chec None Hypertension Diabetes Heart Disease Lung Bisesse	d/quaramed/q	tined in facilitined at hom Other derate offirmed apply if prese	Severe Non-CC Gast Genti Neur	rointestin to-urinary rological D	Case	ritical		
wious COVID-19 rei facility where first Disposition at T mitted in hospital mitted in isolation/que charged to home Health Status a Case Classificat Clinical Informations of Checi mptomatic er 'Ce increase control of the control properties of the control of the control properties of the control of the control properties of the control of the control of the properties of the control of the control of the properties of the control of the control of the properties of the control of the control of the control of the properties of the control of the contro	quarantine t Consult ion* (Reation M/DD/Y k all tha	Report* tine fac If disch it* (Refi efer to A YYYY)* It apply, Dyspne Anorexi Nausea Vomitin Diarred Altered Anosmi	(Provide namility	Discharges	ital/isolat	/mm)* matic	antine facility) Date and Time admit Date and Time isolate Date and Time isolate Date and Time isolate Mild Probable Comorbidities (Chec None Hypertension Diabetes Heart Disease Lung Disease	d/quaramed/q	tined in facilitined at hom Other derate offirmed apply if prese	Severe Non-CC Gast Genti Neur	rointestin to-urinary rological D	Case	Hical		
The second secon	advised that DRUs out all blanks and per grant of the per	advised that DRUs are rough or a che experience plant? Case	and the first production of th	and the state of t	and the first price of the company and the com	advoiced that DRUs are only allowed to obtain a Loopy of accomplished could believe and out all believe and out at electron with the proposal believe the pr	advoid that (ARI) as only allowed to obtain 1 copy of accomplished Of from a control and a fine a	and with full in an only allowed to other 1 capper of accomplished Off from a particut of all chairs and part of accomplished Off from a particut of all chairs and particut of the particut of the particut box. New Year and missel (when N/A). He appointed (Mine Particut Par	and ord that (RDI), are only allowed to other it copy of accomplished OF from a potter. of all oblask and put a clear series with one perspective. Never learn an busis keylor (RI), Beens with ' specified (RI) and the series of the series o	and with fully are only allowed to other 1 copy of accomplished CPF form a pointer, and an analysis of an analysis of the pointer (A). Heres with * are required fix and a fixed pointer (A). Heres with * are required fix and the pointer (A). Heres with * are required fix and the pointer (A). Heres with * are required fix and the pointer (A). Heres with * are required fix and the pointer (A). Heres with * are required fix and the pointer (A). Heres with * are required fix and the pointer (A). Heres with * are required fix and the pointer (A). Heres with * are required fix and the pointer (A). Heres with * are required fix and the pointer (A). Heres with * are required fix and the pointer (A). Here with * are required fix and the pointer	and referred to provide the control of the control	arbord that DRUs are only allowed to solate \ Sept of accomplished OF from a patient. or of all belas and put a sector and, or the appropriate but New Year engulated fields. All dates must be respective fields. All dates fields and respective fields. All dates must be respective fields. All dates must be	out all blanks and put a cleek rank" on the spropriate box. From lever an time blank put in NAU, there with "are required fields. All dates must be in MM/OB perporting Uses" District Spropriate Use District Spropriate District Spropr		

面试后, 请等候叫名字进行核酸检测。 做完检测, 就可以自行离开!



婚姻

Philippine Integrated Disease Surveillance and Response

Case Investigation Form Coronavirus Disease (COVID-19) Version 8



- 1) The Case Investigation Form (CIF) is meant to be administered as an interview by a health care worker or any personnel of the DRU. This is not a self-administered questionnaire.
- 2) Please be advised that DRUs are only allowed to obtain 1 copy of accomplished CIF from a patient.
- 3) Please fill out all blanks and put a check mark on the appropriate box. Never leave an item blank (write N/A). Items with * are required fields. All dates must be in MM/DD/YYYY format.

Disease Reporting Unit*	DRU Region and Province		PhilHealth No.*						
N 61 1 1			Date of later in MAA/DD AAAA						
Name of Interviewer	Contact Number of Intervie	ewer	Date of Interview (MM/DD/YYYY)*						
Name of Informant (if applicable)	Relationship		Contact Number of Informant						
If existing case (check all that apply)* D)	date outcome date case classification date lab result date chest imaging findings Close Contact	Update disposition Update exposure / travel history Others, specify: For RT-PCR Testing (Not a Case of Close Contact)						
Testing Category/Subgroup (Check all that apply, refer to A	ppendix 2)	B	E						
Part 1. Patient Information									
1.1. Patient Profile Last Name*作	First Name (and Suffix)*名		Middle Name* N/A						
		学	IN/A						
Birthdax 台頭/PB/YYY/* 大況Civil Status	Age*年龄 Nationality* 国籍		Sex* 性别 □ Male 男 □ Female 女						
Occupation 职业	Works in a closed setting?	☐ Yes	☐ No ■ Unknown						
1.2. Current Address in the Philippines and Cont		ldress of institution if patient l	lives in closed settings, see 1.5) 目前菲律宾地址						
House No./Lot/Bldg.* 门牌号/楼名 Street/Puro	k/Sitio* 街名	Barangay*	Municipality/City* 城市						
Province* 45	e No. (& Area Code) 家电话-	N/A ■確ellphone No.* 手机号码	G Email Address + 7 + 12 fee						
Province* 省 Home Phon	e No. (& Area Code) 永电话-	子(映elipnone No.** ナガいちゃ	号 Email Address 电子邮箱						
1.3. Permanent Address and Contact Informatio	n (if different from current a	<u>」</u> ddress)永々地址 , 加里跟							
House No./Lot/Bldg. 门牌号/楼名 Street/Puro									
	N (0 A O L) 家由行	N/A	5 1011						
Province 省 Home Phon	e No. (& Area Code) 家电值	号码ellphone No. 手机号码	Email Address 电子邮箱						
1.4. Current Workplace Address and Contact Inf	ormation 工作地址								
Lot/Bldg. 门牌号/楼名 Street	街名	Barangay	Municipality/City 城市						
Province 省 Name of Wo	orkplace 工作场所名称	N/A Phone No./Cellphone No.	手机号码 Email Address 电子邮箱						
Province Name of wo	TKPIACE 工作場別看你	Priorie No./Celipriorie No.	于Wind Email Address 电子邮相						
1.5. Special Population (indicate further details	on exposure and travel histor	ry in Part 3)							
	ion of health facility:	■ No and OFW: □ OFW □ Non-OFW ■ No							
Returning Overseas Filipino* Yes, Country of or Foreign National Traveler* Yes, Country of or	•	and OFW:							
	ality, & Province of origin								
	nded Individual	Authorized Person Outside Residence / Local Traveler							
Lives in Closed Settings* Yes, specify institu		and name: nunities, care homes, camps, etc.)							
Indigenous Person* Yes, specify group		idinics, care nomes, camps, etc.,	, ■ No						
Port 2 Cose Investigation Patrile									
Part 2. Case Investigation Details 2.1. Consultation Information									
Have previous COVID-19 related consultation?	Yes, Date of First Consult	(MM/DD/YYYY)*	No						
Name of facility where first consult was done	an afternative Product	and failth							
2.2. Disposition at Time of Report* (Provide nan Admitted in hospital		antine racility) Date and Time admitted in hos	spital						
Admitted in isolation/quarantine facility		Date and Time isolated/quarantined in facility							
☐ In home isolation/quarantine ☐ Discharged to home If discharged: Date of		Date and Time isolated/quarantined at home							
Discharged to home If discharged: Date of 2.3. Health Status at Consult* (Refer to Appendix	Discharge (MM/DD/YYYY)* _ 3) □ Asymptomatic	☐ Mild ☐ Mo	Others: oderate						
2.4. Case Classification* (Refer to Appendix 1)	□ Suspect		nfirmed						
2.5. Clinical Information									
Date of Onset of Illness (MM/DD/YYYY)*		Comorbidities (Check all that	apply if present)						
Signs and Symptoms (Check all that apply) ☐ Asymptomatic ☐ Dyspnea		□ None	☐ Gastrointestinal						
☐ Fever°C ☐ Anorexia ☐ Cough ☐ Nausea ☐ General weakness ☐ Vomiting ☐ Fatigue ☐ Diarrhea		☐ Hypertension ☐ Genito-urinary ☐ Diabetes ☐ Neurological Disease ☐ Heart Disease ☐ Cancer ☐ Lung Disease ☐ Others							
☐ Headache ☐ Altered Mental Status	/o opuid	Pregnant?	Yes, LMP (<i>MM/DD/YYYY</i>)						
	. w/o any identified cause) w/o any identified cause)		Yes						
☐ Corvza ☐ Others, specify	. ,,	Was diagnosed to have Severe	Acute Respiratory Illness?						

Chest imagin	_		stive	of CO	VID-19															
Date done	_	aging done			Results															
		Chest radio	grap						acities, ofter										عد:ام	
		Chest CT Lung ultras	ounc		_				bilateral ground glass opacities, often rounded in morphology, w/ peripheral & lower lung dist. Fhickened pleural lines, B lines, consolidative patterns with or without air bronchograms											
		None	ounc	'		Other find			i pieurai iirie	3, 0	illies, colls	olluati	re patterns	VVILII	or withou	t all bronci	ograi	115		
26 1		ratory Inform	natio	.			80)													
Have tested p					date of specimen C	ollection (A	1M/D	D/YYYY)*								□ No				
RT-PCR befor		_			ratory*	oncetion (A	1141, 01	D, 1111)			No.	of prev	ious RT-PC	R swa	bs done					
,								of test*	No. of previous RT-PCR swabs done f test* Results*											
					•		<u> </u>	RT-PCR (OPS								☐ Pending ☐ Negative				
								RT-PCR (NPS	. ,							☐ Positive ☐ Equ				
									and NPS)		Others:									
									١	_	A 4: 4	D				Daniellin -	_	NI		
								RT-PCR (OPS RT-PCR (NPS	•		Antigen t	est; Pro	vide reasor	i below	/: 	Pending Positive			gative uivocal	
									,		Antibody	test		_		Others:		Lqu	iivocai	
								Others:			·					o tricis.				
2.7. C	utc	ome/Condit	ion a	t Tim	e of Report*															
☐ Active (cu	ırrer	itly admitted	l/isol	lation,	/quarantine) \Box	Recovered,	date	of recovery	(MM/DD/YYY	Y)*_		[□ Died, da	te of d	leath <i>(MN</i>	1/DD/YYYY)*				
If died,		Imm	edia	te Cau	use:					Ar	ntecedent	Cause:								
cause of deat	th*	Und	erlyii	ng Cai	use:					Co	ontributory	/ Condi	tions:							
		1																		
					d Travel History 持															
					and/or confirmed							ate of	last contac		, ,			_		
					matic, 14 days befo		_	•							Unknowr					
					nown COVID-19 tra					I	_ ′	nternat	ional		Yes, Loca					
			symp	toma	tic, 14 days before				tion? *		No				Unknowr	exposure				
If Internation		avel,						travel dates:	10			_	From:			To:				
country of or					Ti-let A/I Ni		ongo	oing COVID-:	L9 communit	-			Yes	D-4-	-£:1	□ No	'DD ///	000		
Airline/Sea ve	esse				Flight/Vessel Num	oer			Date of dep	artu	ire (MM/D	D/YYYY)	Date	ot arrivai	in PH <i>(MM/</i>	וץ/טט	(
If Local Travo	d cn	ocify traval i	alaco	s (Ch	eck all that apply, p	rovide nar	a of t	acility addr	acc and inclu	ıciva	traval dat	ac in N	4N.4/DD/VVV	v)						
II LOCAI ITAVE	ι, 3μ	ecily travery	Jiace	S (CIIC				acinty, addit	Address	isive	truveraut		nclusive Tr		ates	With on	going	COVI	D-19	
Place Visited					Name of Place	!		(Reaion. Pro	vince, Munic	ipali	itv/Citv)	From		To:	utes	Communi				
☐ Health F	Facili	tv						(111291117)		.,	,,,,	,,,,,,,				☐ Yes	•		No	
☐ Closed S		·														☐ Yes			No	
☐ School																☐ Yes			No	
☐ Workpla	ace															☐ Yes			No	
☐ Market																☐ Yes			No	
☐ Social G	iathe	ring														☐ Yes ☐ No				
☐ Others																☐ Yes			No	
☐ Transpo	ort S	ervice, spec	ify th																	
Airline / Sea v	vesse	el / Bus line /	Train	Fli	ght / Vessel / Bus No	o. Pl	ace of	f Origin	gin Departure Date (MM/DD/YYYY) Destination						n	Date of Arrival (MM/DD/YYYY)				
					ntact numbers of p)	Name (<i>Use</i>	Name (Use the back page if needed) Contact Number											
					onset of illness un															
					ontact numbers of nen was submitted	•	10													
until this date		tient on the	uay :	speciii	nen was submitted	ioi testilig														
arren ema udit	_																			
Appendix 1. CC	OVID	-19 Case Def	nitio	ns																
				SUSP	ECT								PROBAB	LE						
A) A person	wh	meets the	linica	I AND	epidemiological cri	teria		Δ) Λ	patient who r	neet	ts the clinic	al crite	ria (on the l	eft) AN	ID is conta	ct of a prob	able c	r		
- Clinic					cpiacimological cit	terra		1 '	nfirmed case							-			ne	
		onset of feve	r ANE	coug	h OR				nfirmed iden		-									
2) Ac	ute	onset of ANY	THRI	EE OR	MORE of the follow	ing signs or		B) A	suspect case	(on t	the left) wit	h chest	imaging sh	owing	findings s	uggestive of	COVI	D-19		
					ral weakness/fatigue			I	sease. Typical											
	-				yspnea, anorexia / n	ausea/ vomi	ting,	_	Chest radiog			acities,	often round	ded in r	norpholog	y, with perip	heral	and lo	ower	
ا	arrine	ea, altered m	ental	status	. AND			_	lung distribu Chest CT: mi			graund	glass onaci	ties of	ten round	ed in mornh	alogy	with		
– Epide	mio	ogical criteri	а						peripheral a					tics, or	terriounu	cu iii iiioi piii	JIOSY,	WICH		
		-		rea wi	th high risk of transi	nission of th	e viru	s –	Lung ultraso		_			es (mul	tifocal, dis	crete, or cor	fluen	t),		
(e.	g clo	sed resident	ial se	ttings	and humanitarian se	ttings, such	as		consolidative	e pat	tterns with	or with	out air bror	nchogra	ams					
	-			-	displaced persons),	any time w	in the	1 '	person with r			anosmi	a (loss of sr	nell), a	geusia (lo	ss of taste) i	n the	absen	ce of	
		s prior to sym				nemiccion -	nv+i~	I	y other ident			1 in ~-	adula wikk	rocn!	toni dist	see nuonadi	م طمحہ	h Asi	,	
		-			with community tra toms onset; OR	i i i i i i i i i i i i i i i i i i i	yum	1 '	ath, not othe											
					iding w/in the health	n facilities ar	nd w/i		nich has had a		-				-		u	_,	.	
ho	usel	olds, anytim	e w/i	n the	14 days prior to sym	ptom onset	0	R					CONFIDA	ED						
D) A: -		h aa				to uo!							CONFIRM	EU						
					ory illness (SARI: acu sured fever of > 38				L	\ per	rson with la	borato	ry confirma	tion of	f COVID-19) infection				
infection with history of fever or measured fever of ≥ 38°C; cough with onset w/in the last 10 days; and who requires hospitalization)									A person with laboratory confirmation of COVID-19 infection , irrespective of clinical signs and symptoms.											

Appendix 2. Testing Category / Subgroup

- A Individuals with severe/critical symptoms and relevant history of travel/contact
- B Individuals with mild symptoms, relevant history of travel/contact, and considered vulnerable; vulnerable populations include those elderly and with preexisting medical conditions that predispose them to severe presentation and complications of COVID-19
- C Individuals with mild symptoms, and relevant history of travel and/or contact
- D Individuals with no symptoms but with relevant history of travel and/or contact or high risk of exposure. These include:
- D1 Contact-traced individuals
- D2 Healthcare workers, who shall be prioritized for regular testing in order to ensure the stability of our healthcare system
- D3 Returning Overseas Filipino (ROF) workers, who shall immediately be tested at port of entry
- Filipino citizens in a specific locality within the Philippines who have expressed
 intention to return to their place of residence/home origin (Locally Stranded Individuals) may be tested subject to the existing protocols of the IATF
- Frontliners indirectly involved in health care provision in the response against COVID-19 may be tested as follows:
- Those with high or direct exposure to COVID-19 regardless of location may be tested up to once a week. These include: (1) Personnel manning the Temporary Treatment and Quarantine Facilities (LGU and Nationally-managed); (2) Personnel serving at the COVID-19 swabbing center; (3) Contact tracing personnel; and (4) Any personnel conducting swabbing for COVID-19 testing
- Those who do not have high or direct exposure to COVID-19 but who live or work in Special Concern Areas may be tested up to every two to four weeks. These include the following: (1) Personnel manning Quarantine Control Points, including those from Armed Forces of the Philippines, Bureau of Fire Protection; (2) National / Regional / Local Risk Reduction and Management Teams; (3) Officials from any local government / city / municipality health office (CEDSU, CESU, etc.); (4) Barangay Health Emergency Response Teams and barangay officials providing barangay border control and performing COVID-19-related tasks; (5) Personnel of Bureau of Corrections and Bureau of Jail Penology & Management; (6) Personnel manning the One-Stop-Shop in the Management of ROFs; (7) Border control or patrol officers, such as immigration officers and the Philippine Coast Guard; and (8) Social workers providing amelioration and relief assistance to communities and performing COVID-19-related tasks
- F Other vulnerable patients and those living in confined spaces. These include but are not limited to: (1) Pregnant patients who shall be tested during the peripartum period; (2) Dialysis patients; (3) Patients who are immunocompromised, such as those who have HIV/AIDS, inherited diseases that affect the immune system; (4) Patients undergoing chemotherapy or radiotherapy; (5) Patients who will undergo elective surgical procedures with high risk for transmission; (6) Any person who have had organ transplants, or have had bone marrow or stem cell transplant in the past 6 months; (7) Any person who is about to be admitted in enclosed institutions such as jails, penitentiaries, and mental institutions.

- G Residents, occupants or workers in a localized area with an active COVID-19 cluster, as identified and declared by the local chief executive in accordance with existing DOH Guidelines and consistent with the National Task Force Memorandum Circular No. 02 s.2020 or the Operational Guidelines on the Application of the Zoning Containment Strategy in the Localization of the National Action Plan Against COVID-19 Response. The local chief executive shall conduct the necessary testing in order to protect the broader community and critical economic activities and to avoid a declaration of a wider community quarantine.
- H Frontliners in Tourist Zones:
- H1 All workers and employees in the hospitality and tourism sectors in El Nido, Boracay, Coron, Panglao, Siargao and other tourist zones, as identified and declared by the Department of Tourism. These workers and employees may be tested once every four (4) weeks.
- H2 All travelers, whether of domestic or foreign origin, may be tested at least once, at their own expense, prior to entry into any designated tourist zone, as identified and declared by the Department of Tourism.
- I All workers and employees of manufacturing companies and public service providers registered in economic zones located in Special Concern Areas may be tested regularly.

J Economy Workers

- J1 Frontline and Economic Priority Workers, defined as those 1) who work in high priority sectors, both public and private, 2) have high interaction with and exposure to the public, and 3) who live or work in Special Concerns Areas, may be tested every three (3) months. These include but not limited to:
 - **Transport and Logistics**: drivers of taxis, ride hailing services, buses, public transport vehicle, conductors, pilots, flight attendants, flight engineers, rail operators, mechanics, servicemen, delivery staff, water transport workers (ferries, inter-island shipping, ports)
 - **Food Retails**: waiters, waitress, bar attendants, baristas, chefs, cooks, restaurant managers, supervisors
 - **Education**: teachers at all levels of education and other school frontliners such as guidance counselors, librarians, cashiers
 - Financial Services: bank tellers
 - Non-Food Retails: cashiers, stock clerks, retail salespersons
 - **Services:** hairdressers, barbers, manicurists, pedicurists, massage therapists, embalmers, morticians, undertakers, funeral directors, parking lot attendants, security guards, messengers
 - **Construction**: construction workers including carpenters, stonemasons, electricians, painters, foremen, supervisors, civil engineers, structural engineers, construction managers, crane/tower operators, elevator installers, repairmen
 - Water Supply, Sewerage, Waster Management: plumbers, recycling/ reclamation workers, garbage collectors, water/wastewater engineers, janitors, cleaners
 - **Public Sector**: judges, courtroom clerks, staff and security, all national and local government employees rendering frontline services in special concern areas
 - Mass Media: field reporters, photographers, cameramen
- All employees not covered above are not required to undergo testing but are encouraged to be tested every quarter. Private sector employers are highly encouraged to send their employees for regular testing at the employers' expense in order to avoid lockdowns that may do more damage to their companies.

Appendix 3. Severity of the Disease

MILD

Symptomatic patients presenting with fever, cough, fatigue, anorexia, myalgias; other non-specific symptoms such as sore throat, nasal congestion, headache, diarrhea, nausea and vomiting; loss of smell (anosmia) or loss of taste (ageusia) preceding the onset of respiratory symptoms with **NO signs of pneumonia or hypoxia**

MODERATE

- Adolescent or adult with clinical signs of non-severe pneumonia (e.g. fever, cough, dyspnea, respiratory rate (RR) = 21-30 breaths/minute, peripheral capillary oxygen saturation (SpO2) >92% on room air)
- Child with clinical signs of non-severe pneumonia (cough or difficulty of breathing and fast breathing [< 2 months: > 60; 2-11 months: > 50; 1-5 years: > 40] and/or chest indrawing)

SEVERE

- Adolescent or adult with clinical signs of severe pneumonia or severe acute respiratory infection as follows: fever, cough, dyspnea, RR>30 breaths/minute, severe respiratory distress or SpO2 < 92% on room air
- 2. Child with clinical signs of pneumonia (cough or difficulty in breathing) plus at least one of the following:
 - a. Central cyanosis or SpO2 < 90%; severe respiratory distress (e.g. fast breathing, grunting, very severe chest indrawing); general danger sign: inability to breastfeed or drink, lethargy or unconsciousness, or convulsions.
 - Fast breathing (in breaths/min): < 2 months: > 60; 2-11 months: > 50;1-5 years: > 40.

CRITICAL

Patients manifesting with acute respiratory distress syndrome, sepsis and/or septic shock:

1. Acute Respiratory Distress Syndrome (ARDS)

a. Patients with onset within 1 week of known clinical insult (pneumonia) or new or worsening respiratory symptoms, progressing infiltrates on chest X-ray or chest CT scan, with respiratory failure not fully explained by cardiac failure or fluid overload

2. Sepsis

- a. Adults with life-threatening organ dysfunction caused by a dysregulated host response to suspected or proven infection. Signs of organ dysfunction include altered mental status, difficult or fast breathing, low oxygen saturation, reduced urine output, fast heart rate, weak pulse, cold extremities or low blood pressure, skin mottling, or laboratory evidence of coagulopathy, thrombocytopenia, acidosis, high lactate or hyperbilirubinemia
- b. Children with suspected or proven infection and > 2 age-based systemic inflammatory response syndrome criteria (abnormal temperature [> 38.5 °C or < 36 °C); tachycardia for age or bradycardia for age if < 1year; tachypnea for age or need for mechanical ventilation; abnormal white blood cell count for age or > 10% bands), of which one must be abnormal temperature or white blood cell count.

3. Septic Shock

- a. Adults with persistent hypotension despite volume resuscitation, requiring vasopressors to maintain MAP > 65 mmHg and serum lactate level >2mmol/L
- b. Children with any hypotension (SBP < Sth centile or > 2 SD below normal for age) or two or three of the following: altered mental status; bradycardia or tachycardia (HR < 90 bpm or > 160 bpm in infants and heart rate < 70 bpm or > 150 bpm in children); prolonged capillary refill (> 2 sec) or weak pulse; fast breathing; mottled or cool skin or petechial or purpuric rash; high lactate; reduced urine output; hyperthermia or hypothermia.